Healthcare Analyst

Wilfred Yuen

Healthcare analyst with 12+ years’ experience in both sell-side and buy-side leadership roles, with extensive experience IPO experience and a robust network of institutional investors and corporate executives. Coverage spans biopharma, biotech, CROs, devices, and health-tech stocks, delivered through with stock/sector/thematic reports, detailed financial models, and direct corporate access.

China Healthcare Weekly Wrap (27-31 July)

Wuxi Apptec (2359.HK): 2Q Beat on Strong QoQ Growth in TIDES; 2026 Topline Guidance Raised by C.14%

BeOne (ONC.US): 2Q Results Call Takeaway; 2026 Guidance Raised on Strength of Brukinsa; Next up ESMO

Akeso (9926.HK): SMMT 2Q26 Call Takeaways on Ivonescimab

China Healthcare Weekly Wrap (20-24 July)

China Healthcare Weekly Wrap (13-17 July)

Equity Bottom-Up

<ul>
<li>Thanks to last year's salesforce streamline and additional indictions/NRDL inclusions, China in-market sales was up 32% YoY to US$94m, driven by Elunate (+41% YoY) and Sulanda (+45% YoY) in 1H26</li>
<li>Fruzaqla in-market sales was up 14% YoY to US$185m in 1H26, driven by ex-US (+c.70% YoY). Profitability maintained with net profit of US$16m in 1H26. Strong cash position at US$1.4bn</li>
<li>2026 revenue guidance maintained; 2H26 key catalysts: 1) global phase 3 readout SAFFRON (Savolitinib in 2L MET EGRF NSCLC), 2) R&amp;D day, 3) potential BD on ATTC. See more inside</li>
</ul>


Thanks to last year's salesforce streamline and additional indictions/NRDL inclusions, China in-market sales was up 32% YoY to US$94m, driven by Elunate (+41% YoY) and Sulanda (+45% YoY) in 1H26
Fruzaqla in-market sales was up 14% YoY to US$185m in 1H26, driven by ex-US (+c.70% YoY). Profitability maintained with net profit of US$16m in 1H26. Strong cash position at US$1.4bn
2026 revenue guidance maintained; 2H26 key catalysts: 1) global phase 3 readout SAFFRON (Savolitinib in 2L MET EGRF NSCLC), 2) R&amp;D day, 3) potential BD on ATTC. See more inside


Hutchmed (13.HK): 1H26 Call Takeaway: 2026 Guidance Intact; 2H Catalysts: SAFFRON, ATTC BD, R&D Day

HUTCHMED

Hutchmed (13.HK): 1H26 Call Takeaway: 2026 Guidance Intact; 2H Catalysts: SAFFRON, ATTC BD, R&D Day